Decitabine
 |
|
|---|---|
| Systematic (IUPAC) name | |
| 4-amino-1-(2-deoxy-b-D-erythro-pentofuranosyl)- 1,3,5-triazin-2(1H)-one |
|
| Clinical data | |
| Trade names | Dacogen |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a608009 |
| Pregnancy cat. | D |
| Legal status | ℞ Prescription only |
| Routes | Intravenous |
| Pharmacokinetic data | |
| Protein binding | <1% |
| Half-life | 30 minutes |
| Identifiers | |
| CAS number | 2353-33-5  |
| ATC code | L01BC08 |
| PubChem | CID 451668 |
| DrugBank | DB01262 |
| ChemSpider | 397844 |
| UNII | 776B62CQ27 |
| KEGG | D03665 |
| ChEBI | CHEBI:50131 |
| ChEMBL | CHEMBL1201129 |
| Chemical data | |
| Formula | C8H12N4O4 |
| Mol. mass | 228.206 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
|
Decitabine (trade name Dacogen), or 5-aza-2'-deoxycytidine, is a cytidine analog.
Contents |
[edit] Mechanism
It is a hypomethylating agent.[1][2] It hypomethylates DNA by inhibiting DNA methyltransferase.
It functions in a similar manner to azacitidine, although decitabine can only be incorporated into DNA strands while azacitidine can be incorporated into both DNA and RNA chains.
[edit] Clinical uses
Decitabine is indicated for the treatment of myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and Intermediate-1, Intermediate-2, and High-Risk International Prognostic Scoring System groups.
[edit] Chemical Synth
Piml, J.; Sorm, F.; Coll. Czech. Chem. Commun. 1964, 29, 2576.
[edit] Further reading
- Moon C, Kim SH (June 2009). "Use of epigenetic modification to induce FOXP3 expression in naïve T cells". Transplant Proc. 41 (5): 1848–54. doi:10.1016/j.transproceed.2009.02.101. PMID 19545742.
[edit] References
- ^ Kantarjian H, Issa JP, Rosenfeld CS, et al. (April 2006). "Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study". Cancer 106 (8): 1794–803. doi:10.1002/cncr.21792. PMID 16532500.
- ^ Kantarjian HM, O'Brien S, Cortes J, et al. (August 2003). "Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia". Cancer 98 (3): 522–8. doi:10.1002/cncr.11543. PMID 12879469.
[edit] External links
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
